Baricitinib: A Review in Rheumatoid Arthritis

Efficacy of baricitinib in the treatment of rheumatoid arthritis

(2017) Christophe Richez et al.   EXPERT OPINION ON PHARMACOTHERAPY

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis

(2017) Edward C. Keystone et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study

(2017) Yoshiya Tanaka et al.   Modern Rheumatology

Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials

(2017) Yoshiya Tanaka et al.   Modern Rheumatology

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

(2017) Peter C. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis

(2017) Y. H. Lee et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential

(2017) Bindee Kuriya et al.   Therapeutic Advances in Musculoskeletal Disease

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

(2016) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

(2016) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

(2016) Shingo Nakayamada et al.   BIODRUGS

Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study

(2016) Y. Tanaka et al.   JOURNAL OF RHEUMATOLOGY

Baricitinib in Patients with Refractory Rheumatoid Arthritis

(2016) Mark C. Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

(2014) Edward C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers

(2014) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY